PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
The Cystic Fibrosis Foundation’s Whole Genome Sequencing (WGS) project contains WGS data from over 5,000 people with cystic fibrosis in the United States that is linked with data from the CF Foundation Patient Registry.
The purpose of the Screening Improvement Program mechanism is to catalyze efforts aimed at improving the screening system used for early diagnosis.
The Cystic Fibrosis Foundation is requesting applications with a Letter of Intent for innovative, multi-site quality improvement projects that aim to test tools and processes facilitating remote cystic fibrosis care delivery.
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.
The Cystic Fibrosis Foundation is requesting letters of intent for research projects that aim to use available clinical trials in organ transplantation specimens and/or clinical data to improve knowledge of chronic lung allograft dysfunction pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of chronic lung allograft dysfunction.
The intent of this request for applications is to solicit and fund projects that will improve our understanding of the biological basis for the development and progression of gastrointestinal manifestations in cystic fibrosis as well as to identify potential novel therapeutic strategies to manage and treat them.
The Research Additional Mentoring Program (RAMP) Award is designed to enable promising early-career physician scientists seeking additional research mentoring outside of their home academic institutions to enhance their clinical or translational research proficiency and support their development of the necessary clinical research capabilities to become independent investigators.
Multiple Principal Investigator Clinical Awards are offered to provide support for multi-investigator-initiated clinical research projects that have the potential to make an important contribution to the Cystic Fibrosis Foundation’s mission.